Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mana 312 in Post-Transplant AML/MDS
NCT04679194Phase 1Terminated
- Sponsor
- Mana Therapeutics
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Native Immune Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MANA-312 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), sponsored by Mana Therapeutics. Primary endpoints: Maximum Tolerated Dose at 6 months, Recommended Phase 2 Dose at 6 months and 2 more. Started Dec 2020; status: terminated.
02
Drugs
MANA-312
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT04679194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679194.